PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34479089-9	2021	Irisin treatment significantly alleviated ROS accumulation, autophagy disorder, NF-kappaB-Snail pathway activation as well as the phenotype of EndMT by targeting uncoupling protein 2 (UCP2).	irisin	0-6	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	80-89	
32814473-0	2021	Irisin alleviates LPS-induced liver injury and inflammation through inhibition of NLRP3 inflammasome and NF-kappaB signaling.	irisin	0-6	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	105-114	
32814473-10	2021	Our study demonstrated that irisin countered LPS-mediated liver injury via inhibiting apoptosis, NLRP3 inflammasome activation and NF-kappaB signaling.	irisin	28-34	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140	
34546489-9	2022	Moreover, irisin improved PI3K/AKT insulin signaling pathway and inhibited TLR4/NF-kappaB inflammatory signaling pathway in both islets of HFD mice and PA-treated MIN6 cells.	irisin	10-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	80-89	
34546489-11	2022	CONCLUSION: Irisin alleviates lipotoxicity-induced beta-cell insulin resistance and inflammatory response through the activation of PI3K/AKT/FOXO1 signaling pathways and the inhibition of TLR4/NF-kappaB signaling pathways.	irisin	12-18	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	193-202